FIELD: pharmacology.
SUBSTANCE: invention relates to the compound of the formula (I) 
or its pharmaceutically acceptable salt. The invention also relates to a pharmaceutical composition having effects that reduce blood pressure and/or antifibrotic effects comprising a compound of the invention or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient. The compound of the invention is intended for therapeutic treatment of hypertension or prehypertension, prophylactic treatment of fibrosis, therapeutic treatment of fibrosis, therapeutic treatment of hypertension and fibrosis, and treatment of prehypertension and fibrosis in a subject.
EFFECT: reduces blood pressure, has antifibrotic effects.
16 cl, 12 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION AND/OR FIBROSIS | 2014 |
|
RU2661878C2 |
| COMPOSITIONS FOR TREATING FIBROSIS AND FIBROSIS-RELATED CONDITIONS | 2016 |
|
RU2712140C2 |
| COMPOSITIONS FOR TREATMENT OF HYPERTENSION AND/OR FIBROSIS | 2017 |
|
RU2752088C1 |
| COMPOSITIONS FOR TREATING RENAL AND/OR HEPATIC DISORDERS | 2016 |
|
RU2712624C2 |
| COMPOSITIONS AND METHODS OF TREATING RENAL DISORDERS | 2009 |
|
RU2519124C2 |
| COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASE | 2005 |
|
RU2387454C2 |
| PHARMACEUTICAL COMPOSITION INCLUDING RENIN INHIBITOR, CALCIUM CHANNEL BLOCKER AND DIURETIC | 2003 |
|
RU2316318C2 |
| PEPTIDE | 2011 |
|
RU2572623C2 |
| COMPOSITIONS AND METHODS FOR TREATMENT OF AORTA FIBROSIS | 2010 |
|
RU2536223C2 |
| COMPOSITIONS FOR PULMONARY FIBROSIS TREATMENT | 2017 |
|
RU2747801C2 |
